About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Press Releases 2019
Biocon Biologics
/
News – Posts
/
Press Releases
/
Press Releases 2019
Biocon Biologics Symposium on ‘100 years of Insulin – Delivering on Universal Access & Equitable Care’ Resonates Well with Leading KOLs at IDF Congress 2019
Wed, 11-Dec-2019
Posted by: Biocon Biologics
No Comments
Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally
Tue, 03-Dec-2019
Posted by: Biocon Biologics
No Comments
Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.
Mon, 02-Dec-2019
Posted by: Biocon Biologics
No Comments
USFDA Approves Biocon’s sBLA for Pegfilgrastim New Manufacturing Facility
Wed, 27-Nov-2019
Posted by: Biocon Biologics
No Comments
Kiran Mazumdar-Shaw Conferred with Lifetime Achievement Award by Indian Council of Medical Research
Mon, 18-Nov-2019
Posted by: Biocon Biologics
No Comments
Biocon Features in the Prestigious ASIA IP ELITE List for the Fourth Consecutive Year
Tue, 12-Nov-2019
Posted by: Biocon Biologics
No Comments
Biocon’s Biologics Drug Products Facility in Bengaluru Receives EIR from U.S. FDA
Tue, 05-Nov-2019
Posted by: Biocon Biologics
No Comments
Biocon Moves Up to Rank No. 6 on Science Careers’ Top 20 Global Pharma & Biotech Employers List 2019
Mon, 28-Oct-2019
Posted by: Biocon Biologics
No Comments
Biocon Q2FY20 Earnings Revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3%
Wed, 23-Oct-2019
Posted by: Biocon Biologics
No Comments
Biocon Biologics & Just – Evotec Biologics Sign Licensing Deal for a Biosimilar Asset
Thu, 10-Oct-2019
Posted by: Biocon Biologics
No Comments
1
2
3